Pathology Lab Services

FNAC (Fine Needle Aspiration Cytology) is a minimally invasive diagnostic procedure used to obtain cell samples from lumps or masses in various body tissues. A thin, hollow needle is inserted into the lesion to extract cells, which are then examined under a microscope. FNAC is commonly used for evaluating thyroid nodules, breast lumps, lymph nodes, and other suspicious masses. It provides quick results and helps determine whether further investigation or treatment is needed, making it a valuable tool in diagnosing cancers and other conditions.

**Small Biopsy** and **Large Biopsy** are procedures used to obtain tissue samples for diagnostic purposes, but they differ in size and technique. - **Small Biopsy** (often referred to as a needle biopsy) involves removing a small amount of tissue, usually with a fine needle. It is often used for areas that are difficult to access and is less invasive, requiring minimal recovery time. - **Large Biopsy** (such as an excisional or incisional biopsy) involves removing a larger tissue sample or a whole lesion. This type provides more comprehensive information about the tissue architecture and is often used when there is a suspicion of cancer or when a more extensive evaluation is necessary. Both types of biopsies are essential for diagnosing conditions, guiding treatment decisions, and monitoring disease progression.

**Blocks for review with IHC (Immunohistochemistry) small/large panel** refer to tissue samples embedded in paraffin that are prepared for detailed analysis using IHC techniques. - **Small Panel IHC** typically focuses on a limited number of specific markers, which can help identify certain characteristics of the tissue, such as specific types of cancer or cellular responses. This approach is often used when a targeted assessment is needed. - **Large Panel IHC** involves a broader range of markers, allowing for a more comprehensive analysis of the tissue sample. This is particularly useful in complex cases where multiple factors need to be evaluated, such as in tumor profiling or determining the subtype of a malignancy. Both panels aid pathologists in diagnosing diseases, guiding treatment decisions, and providing prognostic information based on the expression of specific proteins in the tissue.

**CSF (Cerebrospinal Fluid) Cytology**, **Urine Cytology**, and **Fluid Cytology** are diagnostic techniques used to examine cells in various bodily fluids for signs of disease, particularly cancer. - **CSF Cytology** involves analyzing cerebrospinal fluid obtained via lumbar puncture. It is crucial for diagnosing central nervous system conditions, including infections, inflammatory diseases, and malignancies like leptomeningeal carcinomatosis. - **Urine Cytology** examines cells from urine to detect abnormalities, such as those seen in urinary tract cancers. It can help identify cancerous cells and assist in monitoring patients with a history of bladder cancer. - **Fluid Cytology** refers to the analysis of cells from other body fluids, such as pleural, peritoneal, or ascitic fluid. This test is useful for diagnosing infections, inflammation, or malignancies in various organs. All three cytology types provide important information for diagnosis, treatment planning, and monitoring disease progression.

A **Pap smear cytology** test, commonly referred to as a Pap test, is a screening procedure used to detect abnormal cells in the cervix. During the test, a healthcare provider collects cells from the cervix using a small brush or spatula, which are then examined under a microscope. The primary purpose of a Pap smear is to identify precancerous changes or cervical cancer early, allowing for timely intervention. It can also detect certain infections and inflammation. Regular Pap smears are an essential part of women’s healthcare, typically recommended every three years for women aged 21 to 65, or in conjunction with HPV testing for those over 30. Early detection through Pap smears significantly reduces the incidence of cervical cancer.

**FNAC slides for review** refer to the glass slides prepared from the cell samples obtained through fine needle aspiration cytology (FNAC). These slides are stained and examined under a microscope by a pathologist. The review of FNAC slides is crucial for diagnosing various conditions, including tumors, infections, and inflammatory diseases. Pathologists assess the cellular characteristics, morphology, and any abnormalities present in the samples to provide a diagnosis. This process is essential for determining the next steps in management, including the need for further testing or treatment options. Proper slide preparation and interpretation are vital for accurate diagnosis and patient care.

**Histopathology blocks for review** refer to tissue samples that have been embedded in paraffin and sectioned into thin slices for microscopic examination. These blocks are created from biopsies or surgical specimens and are crucial for diagnosing diseases, particularly cancers. During review, pathologists examine these blocks to assess the cellular structure, morphology, and any pathological changes in the tissue. The analysis helps determine the presence of disease, its type, grade, and stage, which are vital for guiding treatment decisions. This review process is essential for providing accurate diagnoses and improving patient outcomes in various medical conditions.

**ER, PR, and Her2/Neu** are key receptor status tests used in breast cancer diagnosis and treatment planning: - **ER (Estrogen Receptor)**: This test determines if cancer cells have receptors for estrogen. Positive ER status indicates that the cancer may respond to hormone therapies that block estrogen, which can help slow or stop cancer growth. - **PR (Progesterone Receptor)**: Similar to the ER test, PR assesses whether progesterone receptors are present on cancer cells. Positive PR status can also suggest responsiveness to hormone therapy. - **Her2/Neu (Human Epidermal Growth Factor Receptor 2)**: This test measures the overexpression of the Her2 protein. Her2-positive cancers tend to grow more aggressively but may respond well to targeted therapies, such as trastuzumab (Herceptin). Determining the status of these receptors helps tailor treatment strategies, predict outcomes, and guide management for breast cancer patients.